This month, Gilead suspended its two Covid-19 trials for the promising antiviral remdesivir for moderate-to-severe patients, citing as the reason that the epidemic of Covid-19 has been so well-controlled in China, no eligible patients can be enrolled at present.
As many other regions beset by Covid-19 have implemented measures to control the outbreak, we must consider that there may not be enough patients with Covid-19 to enrol in studies for interventions. Read more here.
Go deeper with GlobalData
